Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Chemoradiation or Brachytherapy for Rectal Cancer
Rectal Cancer
Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants
N/A N=63 Non-Operative Management and Early Response Assessment in Rectal Cancer
Adenocarcinoma of the Lower Rectum
Primary: Clinical Complete Response Rate — 36; 2 Participants
Phase 2 N=124 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Phase 3 N=486 Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Colorectal Cancer
Primary: Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on…
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
N/A N=57 Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery
Rectum Cancer
Primary: The Blood Pressure of the Arterial Arcade — 42.31; 48.50 mmHg
N/A N=16 Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
Rectal Cancer
Primary: Number of Participants With Pathologic Complete Response — 5 Participants
Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
Phase 2 N=79 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Phase 1 N=22 Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Rectal Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2
Phase 2 N=80 Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Rectal Neoplasms
Primary: Rate of T Stage Downstaging — 71 percentage of participants
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
N/A N=150 Ploidy and Stroma in Early Rectal Cancer
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Phase 2 N=39 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Rectal Cancer
Primary: Pathologic Complete Response Rate — 7 participants
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
Phase 2 N=146 Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants
Phase 2 N=37 Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Rectal Cancer
Primary: Clinical Complete Response (cCR) — 0.24 Proportion of Participants
Phase 2 N=180 Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Rectal Cancer
Primary: Number of Patients Achieving Pathologic Complete Response (pCR). — 25; 9; 90; 56 Participants
Phase 2 N=38 Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Rectal Cancer · Liver Metastases
Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719
Phase 2 N=13 SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
Rectal Cancer
Primary: Neoadjuvant Response (NAR) Score — 9.31 Calculated score
Phase 2 N=90 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
Colorectal Cancer
Primary: 3-Year Disease-free Survival — 88.2 percentage of patients
Phase 2 N=139 Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
Primary: Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. — 26.6; 26.7 percentage of participants
Phase 2 N=123 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Colon Adenocarcinoma · Rectal Adenocarcinoma · Stage III Colorectal Cancer AJCC v7
Primary: Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 — 0.43; 0.26 proportion of patients — p=0.0434
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants